Neuronetics Inc (STIM) FinancialsSTIMNeuronetics Inc

Neuronetics Inc (STIM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinic revenue, accounting for 62.5% of total sales, equivalent to $21.53M. Other significant revenue streams include Treatment sessions and NeuroStar Advanced Therapy System. Understanding this composition is critical for investors evaluating how STIM navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Neuronetics Inc maintains a gross margin of 51.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3.61%, while the net margin is -8.33%. These profitability ratios, combined with a Return on Equity (ROE) of -135.26%, provide a clear picture of how effectively STIM converts its operational activities into shareholder value.

In the context of the broader market, STIM competes directly with industry leaders such as ORGO and UTMD. With a market capitalization of $251.45M, it holds a leading position in the sector. When comparing efficiency, STIM's gross margin of 51.06% stands against ORGO's 45.90% and UTMD's 60.56%. Such benchmarking helps identify whether Neuronetics Inc is trading at a premium or discount relative to its financial performance.

Neuronetics has shown improving financial performance with total revenue increasing to $41.6 million in Q2 2026, a 9.1% year-over-year growth, and a narrowed net loss of $3.4 million, down from $10.1 million in the previous year. The gross margin is also improving, expected to be between 48% and 50% for the full year.